EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

(+)‐Trans‐Cannabidiol Is an Agonist at Human CB 2 Receptors

Pedro Bans Burtchaell, Marina Junqueira Santiago iD, Chenxi Wang, Mehdi Hagdoost, Evie J M Clay iD, Dani Mohnot iD, Mark Connor iD

Pharmacology Research & Perspectives · 2026

DOI: 10.1002/prp2.70325 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2026. Verfasst von Pedro Bans Burtchaell und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, University of Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: Receptor, Cannabinoid, CB2, Cannabidiol, Cannabinoid Receptor Agonists. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Australian Research Council, Office of the Chief Scientist and Engineer, Investment NSW, NSW Chief Scientist and Engineer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(−)‐ trans ‐Cannabidiol ((−)‐CBD) is a principal phytocannabinoid from Cannabis sativa . (−)‐CBD has complex pharmacology but is a relatively weak inhibitor of CB 1 and CB 2 receptor signaling. Cannabidiol has two chiral centres and thus four stereoisomers. (+)‐ trans ‐CBD ((+)‐CBD) has a higher affinity than (−)‐CBD at CB 1 and CB 2 , but its pharmacodynamic effects at these receptors are incompletely described. We examined the activity of (+)‐CBD at human CB 1 and CB 2 receptors using a fluorescence‐based assay of membrane potential in AtT20 cells stably expressing CB 1 or CB 2 receptors. (+)‐CBD produced a rapid, concentration‐dependent hyperpolarization in CB 2 ‐expressing cells ( p EC 50 6.63 ± 0.08) with a maximal effect 90% of the response to CP55940. The CB 2 response was blocked by pertussis toxin pretreatment and competitively inhibited by the CB 2 antagonist AM630 (Schild slope 1.1 ± 0.1). (+)‐CBD was a low‐efficacy, low‐potency CB 1 agonist and inhibited somatostatin‐receptor effects at high concentrations (10–30 μM). (+)‐CBD had no effect on the membrane potential of AtT20 wild‐type cells. In silico modeling of ligand interactions with CB 2 indicated that (+)‐CBD but not (−)‐CBD formed an H‐bond with Ser285, a residue crucial for agonist activation of CB 2 . Our data suggests (+)‐CBD acted as a CB 2 agonist via the orthosteric binding site on the receptor. Synthetic CBD, including (+)‐CBD, has previously been administered in clinical trials, presumably without consideration of its potential CB 2 agonist activity. Given the relative safety of (−)‐CBD in people, (+)‐CBD may be a useful drug to explore CB 2 ‐sensitive disease states.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Cannabinoid, CB2CannabidiolCannabinoid Receptor AgonistsHumansReceptor, Cannabinoid, CB1StereoisomerismMembrane PotentialsCyclohexanolsAnimalsDose-Response Relationship, DrugCell LineMolecular Docking SimulationIndoles

Stichwörter der Autor:innen

G protein coupled receptoragonismcannabinoidchirality

Substanzen

Receptor, Cannabinoid, CB2Receptor, Cannabinoid, CB1CannabidiolCannabinoid Receptor AgonistsCyclohexanolsCNR2 protein, human3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanolIndoles

Autor:innen und Institutionen

  • School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, University of Dublin, Dublin, Ireland.
  • Macquarie Medical School, Macquarie University, North Ryde, New South Wales, Australia.
  • Nalu Bio, San Francisco, California, USA.
  • School of Natural Sciences, Macquarie University, Sydney, New South Wales, Australia.
  • School of Biological Sciences, University of Bristol, Bristol, UK.

ORCID-Profile: Marina Junqueira Santiago, Evie J M Clay, Dani Mohnot, Mark Connor

Förderung

  • Australian Research Council
  • Office of the Chief Scientist and Engineer, Investment NSW
  • NSW Chief Scientist and Engineer

Zitieren

APA

Burtchaell, P. B., Santiago, M. J., Wang, C., Hagdoost, M., Clay, E. J. M., Mohnot, D., & Connor, M. (2026). (+)‐Trans‐Cannabidiol Is an Agonist at Human CB 2 Receptors. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70325

Vancouver

Burtchaell PB, Santiago MJ, Wang C, Hagdoost M, Clay EJM, Mohnot D, et al. (+)‐Trans‐Cannabidiol Is an Agonist at Human CB 2 Receptors. Pharmacology Research & Perspectives. 2026. doi:10.1002/prp2.70325

BibTeX
@article{Burtchaell2026,
  author = {Burtchaell, Pedro Bans and Santiago, Marina Junqueira and Wang, Chenxi and Hagdoost, Mehdi and Clay, Evie J M and Mohnot, Dani and Connor, Mark},
  title = {(+)‐Trans‐Cannabidiol Is an Agonist at Human CB 2 Receptors},
  journal = {Pharmacology Research & Perspectives},
  year = {2026},
  doi = {10.1002/prp2.70325}
}
Kostenlos starten →